Background: We evaluated use of the ARCHITECT HIV Ag/Ab Combo assay (HIV Combo; Abbott Diagnostics; available for sale outside the United States only) for detection of acute HIV infection.
Methods: Samples were obtained from a behavioral intervention study (EXPLORE). HIV-uninfected men who have sex with men were enrolled and tested for HIV infection every 6 months. Samples from seroconverters collected at their last seronegative visit (n = 217) were tested individually using 2 HIV RNA assays. Samples with detectable HIV RNA were classified as acute and were tested with HIV Combo. Samples from the enrollment visit (n = 83) and the time of HIV seroconversion (n = 219) were tested with HIV Combo as controls.
Results: Twenty-one samples (9.7%) from the last seronegative visit had detectable HIV RNA and were classified as acute. HIV Combo was positive for 13 of the acute samples (61.9%). Samples not detected by HIV Combo had viral loads of 724-15,130 copies per milliliter. Expected results were obtained for positive and negative controls tested with HIV Combo.
Conclusions: HIV Combo detected nearly two thirds of acute HIV infections identified in this high-risk population by non-pooled HIV RNA assays. HIV Combo may be useful for high-throughput screening to identify individuals with acute HIV infection.
From the *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD; ‡Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Seattle, WA; §New York Blood Center, New York, NY; ∥Division of Infectious Diseases, University of California at Los Angeles, Los Angeles, CA; ¶Department of Medicine, University of Maryland, Baltimore, MD; and #Abbott Diagnostics, Abbott Park, IL.
Received for publication January 30, 2009; accepted April 21, 2009.
Supported by (1) the HIV Prevention Trials Network sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS) (U01-AI-46745, U01-AI-48054, U01-AI068613); (2) the HIV Network for Prevention Trials and sponsored by the NIAID, NIH, DHHS, through contract N01-AI-35173 with Family Health International and contract N01-AI-45200 with Fred Hutchinson Cancer Research Center; and (3) salary support for O. Laeyendecker provided by the Division of Intramural Research, NIAID, NIH.
Prior presentation: Data included in this article was presented at the 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Quebec.
Conflict of interest: J. Hackett, A. Vallari, and S. G. Devare are employees of Abbott Laboratories.
Abbott Diagnostics provided HIV Combo and 3A77 enzyme immunoassay kits.
Correspondence to: Susan H. Eshleman, MD, PhD, Professor, Pathology, Johns Hopkins University School of Medicine, 646 Ross Bldg, 720 Rutland Avenue, Baltimore, MD 21205 (e-mail: firstname.lastname@example.org).
Laboratory methods routinely used for diagnosis of HIV infection are based on detection of anti-HIV antibodies, which typically appear 3-5 weeks after HIV infection.1,2 These methods do not identify individuals with acute (before seroconversion) HIV infection. Many individuals with acute HIV infection are unaware of their infection status3,4 and lack the symptoms typical of acute retroviral illness.3,4 Furthermore, acute HIV infection is often associated with a high concentration of HIV in plasma and genital secretions,5,6 which in turn is associated with increased risk of transmission.7,8 For these reasons, acutely infected individuals are considered to be major drivers of the global HIV epidemic. Identification of individuals with acute HIV infection provides an opportunity for counseling, which has the potential to reduce risk behaviors during the critical period of high viremia, and also offers the possibility of initiating antiretroviral treatment early in infection, if appropriate. Identification of individuals with acute HIV infection also provides important epidemiologic data. In some research settings, analysis of acute HIV infection may complement other methods for estimating HIV incidence rates.
Diagnosis of acute HIV infection relies on detection of HIV virus (typically HIV RNA or p24 antigen) in the absence of anti-HIV antibodies. The APTIMA HIV-1 RNA Qualitative Assay (Gen-Probe, Inc, San Diego, CA) has been cleared by the US Food and Drug Administration for diagnosis of early HIV infection, although claims are limited to individual (non-pooled) plasma specimens. Large surveillance studies have demonstrated that strategies based on pooled HIV RNA testing can be feasible and cost effective for identifying individuals with acute HIV infection.4,8-11 However, the use of RNA detection algorithms is logistically cumbersome, is laborious, and is typically associated with a substantially delayed time to results (7-14 days). In resource-limited settings, where pooled HIV RNA testing may not be feasible, an alternative strategy for identifying individuals with acute HIV infection has been described that combines rapid HIV testing with an ultrasensitive p24 assay.12,13
We evaluated use of a combination HIV antigen-antibody detection system (fourth-generation immunoassay)14 for detecting acute HIV infection by analyzing samples collected in a longitudinal cohort study of men at risk for HIV acquisition.
Source of Specimens
We analyzed samples (plasma or serum) from men who have sex with men who participated in a US behavioral intervention study (the EXPLORE study).15 HIV-uninfected men who have sex with men were enrolled between 1999 and 2001 and tested for HIV infection every 6 months for at least 24 months. HIV infection was assessed at EXPLORE study sites using an enzyme immunoassay (EIA), followed by confirmation with a Western blot or an immunofluorescence assay.15 Specimens were available from seroconverters at enrollment (n = 83), at the last seronegative visit (n = 217), with an indeterminate Western blot (n = 11), and at the time of HIV seroconversion (n = 219).
HIV RNA Testing
Samples from the last seronegative visit were tested individually using the AMPLICOR HIV-1 MONITOR Test, v1.5 (Monitor v1.5; Roche Molecular Systems, Inc, Branchburg, NJ; lower limit of detection: 400 copies/mL) and the APTIMA HIV-1 RNA Qualitative Assay (Gen-Probe Inc; analytical sensitivity: 30 copies/mL).
Seronegative samples positive for HIV RNA using both assays were classified as “acute” and were subsequently tested with (1) ARCHITECT HIV Ag/Ab Combo assay (HIV Combo; Abbott Diagnostics, Wiesbaden, Germany; available for sale outside the United States only), HIV Combo is a chemiluminescent, magnetic, microparticle-based immunoassay run on the automated random access instrument: i2000SR14; (2) Genetic Systems rLAV HIV-1 EIA (Bio-Rad, Redmond, VA); (3) HIVAB HIV-1/HIV-2 (rDNA), referred to as the 3A77 EIA (Abbott Diagnostics, Abbott Park, IL); and (4) Genetic Systems HIV-1/HIV-2 Plus O EIA (Bio-Rad). Samples from other study visits were tested with HIV Combo as controls. All testing performed with HIV Combo was blinded.
We compared the distributions of viral load (VL) values for different sample sets using the Wilcoxon-Mann-Whitney test for 2 samples, using the exact 2-sided P value. These analyses were conducted in SAS 9.13.
To identify individuals with acute (before seroconversion) HIV infection, samples collected approximately 6 months before seroconversion were tested without pooling using the Monitor v1.5 test. Twenty-one of the 217 samples (9.7%) tested positive for HIV RNA with a median VL of 129,845 copies per milliliter (range: 724 to >750,000 copies per milliliter; Table 1). These 21 samples were designated as acute; the 21 samples were collected a median of 180 days before seroconversion (range: 37-390 days). Twenty of the 21 acute samples also tested positive for HIV RNA using the APTIMA HIV-1 RNA Qualitative Assay; 1 sample did not have sufficient serum remaining for testing.
To evaluate the performance of HIV Combo, 334 samples were tested, including (1) 21 acute samples (HIV RNA positive/HIV antibody negative), (2) 83 samples collected from study enrollment (negative controls), (3) 11 samples collected before seroconversion with indeterminate Western blots (median VL: 59,856 copies/mL; range: 3007 to >750,000 copies/mL), and (4) 219 HIV antibody-positive samples (positive controls, confirmed by Western blot or immunofluorescence assay).
HIV Combo was positive for 13 of the 21 acute samples (61.9%). The median VL of the 13 Combo-positive samples was significantly higher than the median VL for the 8 acute samples that tested negative with HIV Combo [662,217 copies/mL (range: 976 to >750,000 copies/mL) vs. 3576 copies/mL (range: 724-15,130 copies/mL), P = 0.0003)]. All enrollment controls tested negative and all Western blot indeterminate and seroconversion (antibody positive) controls tested positive in HIV Combo. The median VL in the indeterminate samples (59,856 copies/mL, range: 3007 to >750,000 copies/mL) was lower than the median VL in HIV Combo-positive acute samples (662,217 copies/mL, range: 976 to >750,000 copies/mL, P = 0.03).
To further define the serostatus of the 21 acute samples, the samples were retested with 3 different EIAs. All 21 samples tested negative with the GS rLAV HIV-1 EIA, a second-generation assay, and all 20 samples available for testing were negative with the Genetic Systems HIV-1/HIV-2 Plus O EIA (1 sample had insufficient volume remaining for testing), a third-generation assay. Three of the 21 samples (14.3%) tested positive with the third-generation 3A77 EIA; all 3 were positive with HIV Combo.
In this study, HIV Combo detected 13 of 21 acute HIV infections (61.9%) in a high-risk population. In all but one case, the VL in the HIV Combo-positive acute samples was >125,000 copies per milliliter. One sample with 976 copies per milliliter most likely tested positive in HIV Combo because it contained low-level anti-HIV antibodies in addition to p24 antigen; this sample tested positive in the IgM-sensitive 3A77 EIA but tested negative in 2 other EIAs. The higher median VL seen among the HIV Combo-positive vs. HIV Combo-negative samples is consistent with results of Fiebig et al,2 where the median VL in individuals with acute HIV infection was approximately 2 log10 higher in subjects with detectable p24 antigen than in those who were HIV RNA positive and p24 antigen negative. Results obtained with antibody-negative acute specimens from EXPLORE are also consistent with previous estimates for the sensitivity of HIV Combo based on analysis of viral isolate dilutions.14 HIV Combo also detected all 11 samples with indeterminate Western blots; the median VL in these samples was lower than the median VL in HIV Combo-positive acute samples. In contrast, a previous study found that the median VL was higher in subjects with indeterminate Western blots than in subjects with p24 antigen-positive acute HIV infection.2
In the United States, pooled HIV RNA testing is the most widely used method for identification of individuals with acute HIV infection.4,10,11 The sensitivity of pooled HIV RNA testing depends on the sensitivity of the HIV RNA assay used and the size of the initial sample pools. For example, if 96 HIV antibody-negative samples are pooled and tested with an HIV RNA assay with a lower level of detection of 50 copies per milliliter HIV RNA, the assay would detect a single acute sample with a VL of 4800 copies per milliliter or more. Fifteen of the 21 acute samples (71.4%) in the EXPLORE cohort had VLs >4800 copies per milliliter. This is similar to the portion of individuals with acute HIV infection who tested positive with HIV Combo (13 of 21 = 61.9%). Moreover, for 5 of the 8 antibody-negative acute samples not detected by HIV Combo, VL values were <4800 copies per milliliter (range: 724-3984 copies/mL). Thus, these samples would likely have been missed by some HIV RNA pooling algorithms. Because samples are tested individually with HIV Combo, sensitivity is not influenced by the number of samples analyzed.
The capacity of HIV Combo to detect acute and chronic infections in a single step offers several advantages over traditional HIV RNA pool testing. These include time to result, throughput, and labor. HIV Combo is run on automated random access instruments. In the present study, an i2000SR instrument was utilized. On this platform, the time to first result is 28 minutes with a throughput of 200 tests per hour. The assay is less labor intensive than pooled HIV RNA testing, and each sample is analyzed only once. In contrast, pooled HIV RNA testing typically involves 3 or 4 stages of testing using progressively smaller sample pools, to determine which and how many of the samples in a positive initial pool are HIV RNA positive.1 These types of algorithms result in delays in reporting results and increase the overall cost of testing. Incorporation of HIV Combo in routine testing paradigms will likely have a significant impact on cost/benefit calculations, even in high-incidence settings. It should be recognized that fourth-generation assays differ in HIV p24 antigen sensitivity, antibody sensitivity, specificity, and performance on genetically divergent strains of HIV-1.16,17 Thus, results obtained in this study for the ARCHITECT HIV Ag/Ab Combo assay, recognized as among the most sensitive in its class,16 may not be directly applicable to other fourth-generation immunoassays.
In many settings, HIV RNA testing algorithms are not feasible or are cost prohibitive. The relative yield provided by the immunoassays on this panel of recent/acute specimens provides a compelling argument for utilization of the most sensitive immunoassays possible. On this panel of acute samples, although there was no incremental yield between the second- to third-generation Genetic System EIAs (both detected 0 of 21), 3A77 (an alternative third-generation assay) detected 3 of 21 samples (14.3%), whereas HIV Combo detected 13 of 21 of the panel members (61.9%). Thus, the fourth-generation Ag/Ab combination assay provided dramatic improvement in sensitivity of detection. These data are consistent with several previous evaluations of fourth-generation assays showing substantial improvement in detection sensitivity and a reduction in the window period relative to antibody-only assays.16,18-21 For samples from acutely infected individuals, limited data are available on the relationship between HIV-1 VL and p24 antigen sensitivity.21 The present study, the first analysis of fourth-generation assay performance on acute HIV-1 infections identified by non-pooled HIV RNA testing, provides additional perspective on the sensitivity of HIV Combo. Studies have demonstrated the benefit of testing fourth-generation HIV assays in both high-risk and low-risk populations.21,22 The recent recommendation in the UK National Guidelines for HIV Testing 2008 to use fourth-generation immunoassays for first-line testing of blood in all health care settings is noteworthy.23 Our results suggest that ARCHITECT HIV Ag/Ab Combo may be useful for detection of acute HIV infection.
The authors thank the EXPLORE study team, the EXPLORE study participants for providing samples and data used in this study, and Teresa Lukaszewska for technical assistance.
1. Pilcher CD, Eron JJ Jr, Galvin S, et al. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest
2. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS
3. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med
4. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med
5. Daar ES, Moudgil T, Meyer RD, et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med
6. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS
7. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med
8. Pilcher CD, McPherson JT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA
9. Quinn TC, Brookmeyer R, Kline R, et al. Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS
10. Patel P, Klausner JD, Bacon OM, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr
11. Priddy FH, Pilcher CD, Moore RH, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr
12. Pascual A, Cachafeiro A, Funk ML, et al. Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay. J Clin Microbiol
13. Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis
14. Hackett J, Swanson P, West D, et al. ARCHITECT HIV Ag/Ab combination assay: correlation of HIV-1 p24 antigen sensitivity and RNA viral load [TUPEB020]. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis and Treatment; July 22-25, 2007; Sydney, Australia.
15. Koblin B, Chesney M, Coates T, et al. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet
16. Ly TD, Ebel A, Faucher V, et al. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods
17. Henquell C, Jacomet C, Antoniotti O, et al. Difficulties in diagnosing group O human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol
18. Weber B, Fall EH, Berger A, et al. Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays. J Clin Microbiol
19. Saville RD, Constantine NT, Cleghorn FR, et al. Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol
20. Kwon JA, Yoon SY, Lee CK, et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods
21. Cunningham P, Downie J, O'Loughlin P, et al. Incremental detection of HIV infections by the HIV antigen/antibody combination assays: an Australian experience. J Med Virol
22. Andersson S, Asjo B, Jenum PA, et al. Relevance of a combined HIV antigen/antibody assay to detect early HIV infections in a low prevalence population: case reports. Clin Lab
23. UK National Guidelines for HIV Testing 2008
. British HIV Association; 2008. Available at: http://www.bhiva.org
. Accessed November 30, 2008.